Print ISSN: 2790-0207

Online ISSN: 2790-0215

Keywords : acute promyelocytic leukemia

ATRA use in Acute Promyelocytic Leukemia

Susan Mahmood

Kirkuk Journal of Medical Sciences, 2022, Volume 10, Issue 1, Pages 64-86
DOI: 10.32894/kjms.2022.174186

        Acute Leukemia is a the result of malignant event or events occurring in early hematopoietic precursor, instead of proliferation and differentiation normally, the affect cells give rise to progency that fail to differentiate and instead continue to proliferate in an uncontrolled fashion.
         Retrospective study, carried between January 2001, and August 2006, Ninety four children ( 15 years of ages) were diagnosed as AML by bone marrow examination (aspirate and sometimes biopsy), twenty two of these children diagnosed as APL, fourteen were treated by chemotherapy and eight of these children treated by ATRA and specific protocol.
        M 2 subtype of AML is most common subtype.
 M 3 second most  common  subtype  of  AML  with  peak  age  of
frequency 10-11 years with female predominance.
 Combined ATRA  with  chemotherapy  for  treatment  of  APL
improves survival rate of children.
 The most  common  complication  of  ATRA  encounter  during
treatment was dryness of skin and mucosa.